Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
05/10/2022 21:34
Oct 5 (Reuters) - Regen BioPharma Inc RGBP.PK :
* REGEN BIOPHARMA, INC. FILES PROVISIONAL PATENT ON CAR-T
CELL
CAPABLE OF ATTRACTING AND EDUCATING NAÏVE T CELLS TO KILL CANCER
Source text for Eikon: ID:nPn3wStwsa
Further company coverage: RGBP.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regen BioPharma
See all newsBrief: Regen Biopharma Prepares Response For FDA Regarding Its Orphan Drug Application For HemaXellerate
Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
Brief: Regen Biopharma, Inc. Receives First Phase Of Confirmatory Study
Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
Brief: Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics